HK Stock MarketDetailed Quotes

02410 TYK MEDICINES-B

Watchlist
  • 55.500
  • +1.000+1.83%
Market Closed Dec 24 12:08 CST
20.58BMarket Cap-43.91P/E (TTM)

About TYK MEDICINES-B Company

Tongyuankang Pharmaceutical was founded in November 2017, established a 30,000 square meter new drug research and development center in Changxing Life Science Park in Huzhou, Zhejiang, then established the company's administrative headquarters, clinical medicine department and business development department in Shanghai, set up a small molecule drug screening platform in Zhengzhou, and is building new drug formulation plants in Changxing and Shanghai's Songjiang district. It is one of the few innovative biomedical high-tech companies in China with drug development and production capabilities.

Company Profile

Symbol02410
Company NameTYK MEDICINES-B
ISINCNE100006L34
Listing DateAug 20, 2024
Issue Price12.10
Shares Offered47.88M share(s)
FoundedNov 2, 2017
Registered AddressChina
Chairmanyusheng wu
Secretaryyongyijiangmingyu huang
Audit InstitutionErnst & Young
Company CategoryOther
Registered OfficeRoom 1403-2, 14th Floor, Block A, Changxing World Trade Center, No. 1278 Mingzhu Road, Changxing Economic Development Zone, Huzhou, Zhejiang, China
Head Office and Principal Place of BusinessRoom 1901, 19th floor, Lee Garden One, 33 Hysan Avenue, Causeway Bay, Hong Kong
Fiscal Year Ends12-31
Employees147
MarketHong Kong motherboard
Phone(021)61676766;(0572)6088932;(0371)60296579
Fax(021)60107317
EmailBD@tykmedicines.com;investors@tykmedicines.com
Websitehttp://www.tykmedicines.com
Business Zhejiang Tongyuankang Pharmaceutical Co., Ltd. is a Chinese company dedicated to developing and commercializing pharmaceutical products. The company focuses on small molecule drug development, and its main products include TY-9591, TY-302, and TY-2136. TY-9591 is a third-generation EGFR-TKI with anti-tumor effects on EGFR mutations. TY-302 is a potent and selective oral CDK4/6 inhibitor developed to treat advanced solid tumors such as breast cancer and prostate cancer. TY-2136b is an independently developed and orally administered ROS1/NTRK inhibitor for the treatment of solid tumors.

Company Executives

  • Name
  • Position
  • Salary
  • yusheng wu
  • Chairman, President, Executive Director, Chairman of the Nomination Committee, Remuneration Committee Members
  • 2.88M
  • mingyu jiang
  • VP, Executive Director, Joint Company Secretary, Board Secretary, Authorized Representative
  • --
  • jun li
  • Non-executive Directors, Audit Committee Members
  • 902.00K
  • hong gu
  • Non-executive Directors
  • --
  • xiaoying meng
  • Non-executive Directors
  • --
  • chao he
  • Non-executive Directors
  • --
  • zhao ding
  • Non-executive Directors
  • --
  • senquan zhang
  • Independent Non-Executive Director, Chairman of the Audit Committee, Remuneration Committee Members, Nomination Committee Members
  • --
  • yuting leng
  • Independent Non-Executive Director, Remuneration Committee Chairman, Audit Committee Members, Nomination Committee Members
  • --
  • wenqing xu
  • Independent Non-Executive Director
  • --
  • xiuhua shen
  • Independent Non-Executive Director
  • --
  • chengshan niu
  • Senior Director of Pharmaceutical Chemistry, Chairman of the Supervisory Board, Employee Representative Supervisor
  • 1.50M
  • apeng liang
  • Director of Pharmacology, Employee Representative Supervisor
  • 1.46M
  • jing shang
  • Shareholders' Representatives and Supervisors
  • --
  • shaoqing chen
  • Senior Vice President of Pharmaceuticals
  • --
  • xiugui chen
  • Senior Vice President of Clinical Registries
  • --
  • yongyi huang
  • Joint Company Secretary, Authorized Representative
  • --
Heat List
HK
Overall
Symbol
Price
% Chg

No Data

Investment Theme Recent IPOs
Recent IPOs
Intraday+1.20%